INTEGRA Biosciences and Parse Biosciences offer affordable, automated single cell RNA sequencing

FHS
July 26, 2024
6:16 am

INTEGRA Biosciences and Parse Biosciences have partnered to automate single cell RNA sequencing (scRNA-seq) on the ASSIST PLUS pipetting robot.

Lonnie Moulder’s Zenas closes a $200M Series C to broaden lead drug’s autoimmune potential

Lonnie Moulder’s latest biotech has secured some new cash to expand its work in autoimmune diseases. The startup, Zenas BioPharma, closed a $200 million Series

May 8, 2024

KT-253 by Kymera Therapeutics for Myeloproliferative Disorders: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 5, 2023

Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee. – Biotech Investments

Spexis AG / Key word(s): Miscellaneous 22-Jul-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely

July 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.